Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen System

News provided by

Companion Medical

Dec 14, 2017, 08:29 ET

SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- Companion Medical, a leader in the development of advanced technology to improve diabetes care, announced today that it has begun commercial sales of the InPen® system in the United States.  InPen is available by prescription only and is a covered benefit under many insurance plans.  The InPen is for use with U-100 Lilly Humalog® and Novo Nordisk Novolog® rapid-acting insulin and indicated for persons aged 12 years and older.

InPen is similar in size and shape to a traditional insulin pen. It comes in 3 colors to help avoid drug confusion.
InPen is similar in size and shape to a traditional insulin pen. It comes in 3 colors to help avoid drug confusion.
The Companion App home screen gives a summary of your current data. It provides last dose and last blood glucose information, an active insulin display (like an insulin pump) and a graphical depiction of the last 10 hours. In addition, you can access the dose calculator to help with the diffcult calculations required for insulin dosing.
The Companion App home screen gives a summary of your current data. It provides last dose and last blood glucose information, an active insulin display (like an insulin pump) and a graphical depiction of the last 10 hours. In addition, you can access the dose calculator to help with the diffcult calculations required for insulin dosing.

"I am pleased to announce the commercial launch of InPen.  The InPen system is a significant step toward true integrated diabetes management," said CEO Sean Saint.  "Our team has worked diligently to develop a solution for people living with diabetes who want the benefits of an insulin pump without the cost or burden of being tethered to a device."

InPen is the first and only FDA-cleared solution that combines an insulin injector pen with an intuitive smartphone app and bolus advisor using Bluetooth® technology.  InPen tracks insulin doses, including priming, and automatically sends the data to the user's mobile device, providing decision support for the constant monitoring and calculating necessary for successful insulin therapy.  InPen includes technology to:

  • Calculate and recommend optimal dosing;
  • Track history and timing of doses for a full year;
  • Monitor insulin temperature;
  • Remind the user when to take insulin;
  • Display last dose and insulin-on-board; and
  • Generate actionable reports for the healthcare provider.

The InPen app is compatible with iOS 10 and later and is available on the Apple Store.  The app for Android is under development with expected release in Q2 2018.  The InPen app allows glucose data from blood glucose meters and continuous glucose monitors to integrate with the app via integration with Apple Health.

For more information, visit www.companionmedical.com.

About Companion Medical

Companion Medical, Inc. (www.companionmedical.com) is a privately held company based in San Diego, CA.  The company leverages cross-functional engineering expertise, clinical experience, and first-hand knowledge of diabetes lifestyles to develop innovative solutions for diabetes management.

Sean Saint
187601@email4pr.com 
858-522-0252

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/companion-medical-announces-us-commercial-launch-of-smart-insulin-pen-system-300571413.html

SOURCE Companion Medical

Related Links

http://www.companionmedical.com

You just read:

Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen System

News provided by

Companion Medical

Dec 14, 2017, 08:29 ET